INTRODUCTION. This issue focuses on amyloid heart disease and related diagnostic and therapeutic challenges. The articles explore topics such as disease burden, delayed diagnosis, and evolving clinical guidance, while highlighting recent trial findings on stabilizers, silencers, and combination therapies. Additionally, the issue addresses biomarker kinetics, mortality benefits, and practical considerations for integrating new evidence into patient care.
